Selection of iPSCs without mtDNA deletion for autologous cell therapy in a patient with Pearson syndrome.
Sign Up to like & getrecommendations! Published in 2023 at "BMB reports"
DOI: 10.5483/bmbrep.2022-0204
Abstract: Screening for genetic defects in the cells should be examined for clinical application. The Pearson syndrome (PS) patient harbored nuclear mutations in the POLG and SSBP1 genes, which could induce systemic large-scale mitochondrial genome (mtDNA)… read more here.
Keywords: mtdna deletion; deletion; pearson syndrome; autologous cell ... See more keywords